CSBTF (Kuros Biosciences) Growth Rank: 9 (As of Jul. 15, 2026) — 80% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSBTF Kuros Biosciences Ltd CSBTF
72 GF Score
Price $25.57
GF Value $51.52
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Kuros Biosciences Growth Rank?

Kuros Biosciences CSBTF 72 Growth Rank is 9 as of Jul. 15, 2026, which is 80% above its 10-year median of 5.00. GuruFocus rates CSBTF with a GF Score™ of 72/100 and a GF Value™ of $51.52 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Kuros Biosciences has the Growth Rank of 9.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Kuros Biosciences Growth Rank Related Terms

CSBTF vs ABT, SYK, MDT: Growth Rank Comparison

For the Medical Devices subindustry, Kuros Biosciences's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kuros Biosciences Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Growth Rank distribution charts can be found below:

* The bar in red indicates where Kuros Biosciences's Growth Rank falls into.


CSBTF
72GF Score
Kuros Biosciences Ltd CSBTF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 9 mean?
Kuros Biosciences (CSBTF) has a Growth Rank of 9 as of Jul. 15, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Kuros Biosciences and its competitors. This is 80% above median its historical median of 5.00. Over the past decade, Kuros Biosciences' Growth Rank has ranged from 1.00 to 10.00.
Is Kuros Biosciences' Growth Rank too high?
Kuros Biosciences' current Growth Rank of 9 is 80% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Kuros Biosciences has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Growth Rank compare to ABT and SYK?
Kuros Biosciences' Growth Rank of 9 can be compared against companies in the Medical Devices & Instruments industry. Historically, Kuros Biosciences' own Growth Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Kuros Biosciences and its competitors. Kuros Biosciences's current Growth Rank is 9, which is 80% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $51.52, compared to a current price of $25.57 — trading 50.4% below its estimated fair value. The current Growth Rank is 9, which is 80% above median its 10-year median of 5.00. Kuros Biosciences' overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Growth Rank is 9 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kuros Biosciences (CSBTF) Overvalued in 2026?

Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued. The current stock price of $25.57 is trading 50.4% below its estimated GF Value™ of $51.52. GuruFocus considers Kuros Biosciences to be Significantly Undervalued.

Key valuation signals for CSBTF:

  • Growth Rank: 9 (80% above median its 10-year median of 5.00)
  • GF Value™: $51.52 vs. price of $25.57 (50.4% below fair value)
  • GF Score™: 72/100 with 2 warning signs

No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kuros Biosciences Business Description

Address Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
72GF Score

Get the complete analysis for CSBTF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.57
Price
$51.52
GF Value